Zhejiang Qianjiang Biochemical Co., Ltd Class A

Zhejiang Qianjiang Biochemical Co., Ltd Class A

SSSE:600796
4.69
CNY
-0.01
(-0.21%)
0.16EPS
31.30P/E
4.43BMarket Cap
Zhejiang Qianjiang Biochemical Co., Ltd Class A
SSE:600796
(Shanghai Stock Exchange)

Recent

price

4.69

P/E

ratio

31.30

div

yld

1.55%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.57
1.67
1.52
1.57
1.24
1.61
1.49
1.6
1.49
1.19
2.95
3.02
2.34
2.32
1.99
1.93
1.84
Revenue per Share
0.18
0.03
0.06
0.1
0.07
0.09
0.11
0.14
-0.15
0.06
0.15
0.22
0.24
0.24
0.18
0.19
0.16
Basic EPS, GAAP
-0.68
-0.01
0.18
0.09
0.09
0.06
-0.03
0.09
0.02
0.03
0.07
-0.3
0.04
0.13
-0.5
0.2
- -
Free Cash Flow per Basic Share
0.04
0.09
0.11
0.07
0.08
0.04
0.03
0.07
0.05
0.01
0.11
0.12
0.23
0.2
0.11
0.11
0.07
Dividend per Share
1.59
1.61
1.67
1.77
1.81
1.9
2.01
2.1
1.92
1.98
6.18
3.34
3.48
3.62
3.78
3.97
4.09
Book Value per Share
1.47
1.51
1.57
1.67
1.73
1.82
1.93
2.01
1.83
1.9
-2.5
0.31
0.4
0.57
0.26
0.07
0.53
Tangible Book Value per Share
276
335
294
306
320
295
298
293
298
320
641
672
859
878
889
876
879
Basic Weighted Avg Shares
432
559
446
482
398
474
444
468
443
380
1,888
2,031
2,009
2,034
1,768
1,694
1,620
Sales/Revenue/Turnover
2.07
1.29
-7.89
9.39
5.39
11.22
10.05
9.6
1.78
10.07
15.41
15.06
13.58
14.07
12.22
14.38
15.59
Operating Margin (%)
33
31
28
36
38
42
44
44
45
44
166
183
236
225
234
193
- -
Depreciation Expense
50
10
18
31
22
27
33
41
-45
19
96
148
206
211
160
166
143
Net Income, GAAP
0.23
18.41
21.48
17.22
16.73
18.75
14.8
8.86
- -
13.61
29.67
22.4
20.88
20.08
28.1
22.72
15.95
Effective Tax Rate (%)
11.5
1.8
3.95
6.36
5.62
5.6
7.39
8.77
-10.08
5.04
5.09
7.28
10.26
10.36
9.05
9.82
8.85
Profit Margin (%)
49
-299
-12
42
167
211
211
182
209
247
-134
422
588
386
744
521
669
Working Capital
- -
82
51
- -
- -
- -
- -
- -
- -
- -
964
1,292
1,363
975
1,741
1,403
1,222
LT Debt
613
499
518
552
567
597
635
664
613
634
2,479
3,304
3,402
3,497
3,557
3,705
3,810
Total Equity
5.97
0.22
-7.29
2.35
1.32
3.33
2.89
6.52
- -
4.08
5.23
3.59
3.68
3.49
2.13
2.73
- -
Return on Invested Capital (%)
7.13
3.96
5.03
5.54
4.05
3.94
4.11
5.06
- -
2.12
3.06
4.17
5.6
5.83
4.47
3.84
- -
Return on Capital (%)
10.87
2.08
3.57
5.92
4.15
4.75
5.57
6.63
-7.38
3.26
7.82
6.22
6.98
6.85
4.99
4.95
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
410
423
473
LT Borrowings
1,400
1,344
1,221
LT Finance Leases
2
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
867
867
867
Market Capitalization
5,711
4,021
4,428

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,174
2,203
2,283
Cash, Cash Equivalents & STI
855
864
886
Accounts Receivable, Net
760
895
956
Inventories
168
168
183
Total Current Liabilities
1,491
1,614
1,613
Payables & Accruals
- -
- -
- -
ST Debt
410
423
473
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
34.26%
8.98%
4.17%
Free Cash Flow
-122.24%
-203.18%
-140.09%
Net Income, GAAP
17.33%
15.07%
3.98%
Sales/Revenue/Turnover
36.65%
-1.91%
-4.22%
Total Cash Common Dividend
210.85%
20.9%
-3.35%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
374
489
438
468
1,768
2025
378
402
- -
495
1,694
2026
319
415
392
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.06
0.05
0.04
0.18
2025
0.04
0.09
- -
0.02
0.19
2026
0.04
0.05
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.06
0.03
0.01
0.11
2025
- -
0.05
- -
- -
0.11
2026
0.01
0.03
0.02
- -
- -
Business
Zhejiang Qianjiang Biochemical Co., Ltd, founded in 1997 and headquartered in Zhejiang, China, operates primarily in the chemical and biochemical industry specializing in biopesticides, bio-veterinary medicines, and biological pharmaceuticals. The company produces and sells a diverse range of biologically based products including biopesticides consisting of plant growth regulators such as gibberellic acid and gibberellic acid A4+A7; insecticides including abamectin, methylamino abamectin, and avermectin; bactericides like the Jinggangmycin series and proconazole; biological drugs including colistin sulfate premix and related intermediates; and feed additives. It also offers environmental treatment services covering water supply, sewage treatment, solid and hazardous waste landfill and incineration, and food waste disposal. The company distributes its products primarily within China but maintains an international sales network covering Europe, Asia, South America, and Southeast Asia. Recent major developments include a significant capital infusion from Haining Water Investment Group amounting to approximately CNY 356 million aimed at supporting new facility construction and operational optimization. Zhejiang Qianjiang is undergoing a major assets reorganization involving land resumption and industrial upgrading facilitated by collaborations with state-owned entities in the Haining Economic Development Zone. These strategic partnerships and facility expansions underscore its ongoing business transformation towards enhanced production capacity and advanced technology application. The company continues to leverage its proprietary research capabilities, including personalized microbial technology systems, to drive innovation in agricultural and veterinary biochemical products. Zhejiang Qianjiang Biochemical stands as a key player in China's bio-based chemical industry, recognized for its advanced production technology and a robust technical and R&D infrastructure. It maintains a comprehensive product portfolio and a strategic focus on environmentally sustainable solutions alongside its biochemical product lines, catering primarily to agriculture, veterinary medicine, environmental management, and related industrial sectors. The company remains publicly listed with its shares traded on the Shanghai Stock Exchange (Ticker: 600796.SS). It employs over 2,000 staff and consistently pursues technological and operational enhancements aimed at long-term sustainable growth and shareholder value creation.